FinsnoBio, and sister company NysnoBio, are developing mitophagy enhancers using gene therapy and small molecule approaches based on genetic targets in Parkinson’s disease.

San Francisco | October 20, 2023 – Dr. Johnston’s team has been working on the identification of small molecule modulators of the E3 ubiquitin ligase, Parkin, for the last 18 years.

In conjunction with the BIO 2021 conference, Snøhamer Group and FinsnoBio proudly announce a new drug discovery partnership with the world’s leading x-ray crystallography enterprise Accelero Biostructures. FinsnoBio, sister to gene-therapy company NysnoBio, works to